Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2013 1
2016 5
2017 1
2018 4
2019 1
2020 3
2021 4
2022 2
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Preclinical radiolabeling, in vivo biodistribution and positron emission tomography of a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2.
Wichmann CW, Burvenich IJG, Guo N, Rigopoulos A, McDonald A, Cao D, O'Keefe GJ, Gong SJ, Gan HK, Scott FE, Pore N, Coats S, Scott AM. Wichmann CW, et al. Nucl Med Biol. 2023 Jul-Aug;122-123:108366. doi: 10.1016/j.nucmedbio.2023.108366. Epub 2023 Jul 14. Nucl Med Biol. 2023. PMID: 37473513
Automated radiosynthesis of [89Zr]Zr-DFOSq-Durvalumab for imaging of PD-L1 expressing tumours in vivo.
Wichmann CW, Poniger S, Guo N, Roselt P, Rudd SE, Donnelly PS, Blyth B, Van Zuylekom J, Rigopoulos A, Burvenich IJG, Morandeau L, Mohamed S, Nowak AK, Hegi-Johnson F, MacManus M, Scott AM. Wichmann CW, et al. Among authors: burvenich ijg. Nucl Med Biol. 2023 May-Jun;120-121:108351. doi: 10.1016/j.nucmedbio.2023.108351. Epub 2023 May 16. Nucl Med Biol. 2023. PMID: 37224789 Free article.
A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers.
Gan HK, Parakh S, Lee FT, Tebbutt NC, Ameratunga M, Lee ST, O'Keefe GJ, Gong SJ, Vanrenen C, Caine J, Giovannetti M, Murone C, Scott FE, Guo N, Burvenich IJG, Paine C, Macri MJ, Kotsuma M, Senaldi G, Venhaus R, Scott AM. Gan HK, et al. Among authors: burvenich ijg. Invest New Drugs. 2022 Aug;40(4):747-755. doi: 10.1007/s10637-022-01237-3. Epub 2022 Apr 11. Invest New Drugs. 2022. PMID: 35404015 Clinical Trial.
Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin.
Gan HK, Parakh S, Lassman AB, Seow A, Lau E, Lee ST, Ameratunga M, Perchyonok Y, Cao D, Burvenich IJG, O'Keefe GJ, Rigopoulos A, Gomez E, Maag D, Scott AM. Gan HK, et al. Among authors: burvenich ijg. Neurooncol Adv. 2021 Aug 3;3(1):vdab102. doi: 10.1093/noajnl/vdab102. eCollection 2021 Jan-Dec. Neurooncol Adv. 2021. PMID: 34549181 Free PMC article.
Radiolabelling and preclinical characterization of 89Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa.
Burvenich IJG, Goh YW, Guo N, Gan HK, Rigopoulos A, Cao D, Liu Z, Ackermann U, Wichmann CW, McDonald AF, Huynh N, O'Keefe GJ, Gong SJ, Scott FE, Li L, Geng W, Zutshi A, Lan Y, Scott AM. Burvenich IJG, et al. Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3075-3088. doi: 10.1007/s00259-021-05251-0. Epub 2021 Feb 19. Eur J Nucl Med Mol Imaging. 2021. PMID: 33608805
ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
Centenera MM, Scott JS, Machiels J, Nassar ZD, Miller DC, Zinonos I, Dehairs J, Burvenich IJG, Zadra G, Chetta PM, Bango C, Evergren E, Ryan NK, Gillis JL, Mah CY, Tieu T, Hanson AR, Carelli R, Bloch K, Panagopoulos V, Waelkens E, Derua R, Williams ED, Evdokiou A, Cifuentes-Rius A, Voelcker NH, Mills IG, Tilley WD, Scott AM, Loda M, Selth LA, Swinnen JV, Butler LM. Centenera MM, et al. Among authors: burvenich ijg. Cancer Res. 2021 Apr 1;81(7):1704-1718. doi: 10.1158/0008-5472.CAN-20-2511. Epub 2021 Feb 5. Cancer Res. 2021. PMID: 33547161
26 results